Nelivaptan (
INN)
(developmental codename SSR-149,415) is a
selective,
orally active
Oral administration is a route of administration where a substance is taken through the mouth. Per os abbreviated to P.O. is sometimes used as a direction for medication to be taken orally. Many medications are taken orally because they are in ...
,
non-peptide vasopressin receptor antagonist selective for the
V1B subtype.
The drug had entered
clinical trials for treatment of anxiety and depression.
In July 2008,
Sanofi-Aventis announced that further development of this drug had been halted.
See also
*
ABT-436
ABT-436 is an orally active, highly selective vasopressin V1B receptor antagonist which was under development by Abbott Laboratories and AbbVie for the treatment of major depressive disorder, anxiety disorders, and alcoholism but was discon ...
*
Balovaptan
Balovaptan (; developmental code name RG7314), is a selective small molecule antagonist of the vasopressin V1A receptor which is under development by Roche for the treatment of autism. As of August 2019, it is in a phase III clinical trial ...
*
SRX-246
SRX246, also known as API-246, is a small-molecule, centrally-active, highly-selective vasopressin V1A receptor antagonist which is under investigation by Azevan Pharmaceuticals for the treatment of affective and anger disorders. It is an az ...
*
TS-121
TS-121 (THY1773) is an orally active, selective vasopressin V1B receptor antagonist which is under development by Taisho Pharmaceutical for the adjunctive treatment of major depressive disorder. As of May 2017, it is in phase II clinical tri ...
References
External links
*
Sanofi
Vasopressin receptor antagonists
{{systemic-hormonal-drug-stub